MA30006B1 - Composes anti-hypercholesterolemiques - Google Patents
Composes anti-hypercholesterolemiquesInfo
- Publication number
- MA30006B1 MA30006B1 MA30894A MA30894A MA30006B1 MA 30006 B1 MA30006 B1 MA 30006B1 MA 30894 A MA30894 A MA 30894A MA 30894 A MA30894 A MA 30894A MA 30006 B1 MA30006 B1 MA 30006B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- cholesterol
- hypercholesterolemic compounds
- hypercholesterolemic
- esters
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Cette invention fournit des inhibiteurs de l'absorption du cholestérol de formule 1 et les sels pharmaceutiquement acceptables et esters de ceux-là. Les composés sont utiles pour abaisser les niveaux du cholestérol plasmatique, en particulier le LDL-cholestérol, et pour le traitement et la prévention de l'athérosclérose et des événements de la maladie athéroscléreuse.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72378105P | 2005-10-05 | 2005-10-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30006B1 true MA30006B1 (fr) | 2008-12-01 |
Family
ID=37845278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30894A MA30006B1 (fr) | 2005-10-05 | 2008-05-02 | Composes anti-hypercholesterolemiques |
Country Status (25)
Country | Link |
---|---|
US (2) | US20090137546A1 (fr) |
EP (1) | EP1934175B1 (fr) |
JP (1) | JP4879991B2 (fr) |
KR (1) | KR20080050610A (fr) |
CN (1) | CN101277930A (fr) |
AR (1) | AR058068A1 (fr) |
AT (1) | ATE488495T1 (fr) |
AU (1) | AU2006302584B2 (fr) |
BR (1) | BRPI0616834A2 (fr) |
CA (1) | CA2624481C (fr) |
CR (1) | CR9903A (fr) |
DE (1) | DE602006018341D1 (fr) |
DO (1) | DOP2006000211A (fr) |
EA (1) | EA200801008A1 (fr) |
ES (1) | ES2354460T3 (fr) |
GT (1) | GT200600444A (fr) |
IL (1) | IL190434A0 (fr) |
MA (1) | MA30006B1 (fr) |
NO (1) | NO20082075L (fr) |
PE (1) | PE20070493A1 (fr) |
SV (1) | SV2009002863A (fr) |
TN (1) | TNSN08153A1 (fr) |
TW (1) | TW200806623A (fr) |
WO (1) | WO2007044318A2 (fr) |
ZA (1) | ZA200802587B (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7176193B2 (en) * | 2002-06-19 | 2007-02-13 | Sanofi-Aventis Deutschland Gmbh | Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
GB0215579D0 (en) * | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
WO2005061452A1 (fr) * | 2003-12-23 | 2005-07-07 | Astrazeneca Ab | Derives diphenylazetidinone a activite inhibitrice de l'absorption du cholesterol |
GB0329778D0 (en) * | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
WO2005062824A2 (fr) * | 2003-12-23 | 2005-07-14 | Merck & Co., Inc. | Composes anti-hypercholesterolemie |
UY29607A1 (es) * | 2005-06-20 | 2007-01-31 | Astrazeneca Ab | Compuestos quimicos |
AR057072A1 (es) * | 2005-06-22 | 2007-11-14 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto |
AR054482A1 (es) * | 2005-06-22 | 2007-06-27 | Astrazeneca Ab | Derivados de azetidinona para el tratamiento de hiperlipidemias |
AR057383A1 (es) * | 2005-06-22 | 2007-12-05 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto |
AR057380A1 (es) * | 2005-06-22 | 2007-11-28 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos |
SA06270191B1 (ar) * | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
TW200806623A (en) * | 2005-10-05 | 2008-02-01 | Merck & Co Inc | Anti-hypercholesterolemic compounds |
DE102005055726A1 (de) * | 2005-11-23 | 2007-08-30 | Sanofi-Aventis Deutschland Gmbh | Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
TW200811098A (en) * | 2006-04-27 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
WO2008085300A1 (fr) * | 2006-12-20 | 2008-07-17 | Merck & Co., Inc. | Composé anti-hypercholestérolémique |
US8029405B2 (en) | 2008-05-30 | 2011-10-04 | Hyundai Motor Company | Gear train of automatic transmission for vehicles |
WO2010056788A1 (fr) * | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Composés anti-hypercholestérolémiques |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2107548T3 (es) * | 1991-07-23 | 1997-12-01 | Schering Corp | Compuestos de beta-lactama sustituidos utiles como agentes hipocolesterolemicos y procedimientos para su preparacion. |
US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
CA2191455A1 (fr) * | 1994-06-20 | 1995-12-28 | Wayne Vaccaro | Composes d'azetidinone substitues utilises comme agent hypercholesterolemiant |
US5624920A (en) * | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
BR0116325A (pt) * | 2000-12-21 | 2003-10-14 | Aventis Pharma Gmbh | 1,2-difenilazetidinonas, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação para o tratamento de distúrbios do metabolismo de lipìdios |
TWI291957B (en) * | 2001-02-23 | 2008-01-01 | Kotobuki Pharmaceutical Co Ltd | Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same |
US7176193B2 (en) * | 2002-06-19 | 2007-02-13 | Sanofi-Aventis Deutschland Gmbh | Acid-group-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
US7176194B2 (en) * | 2002-06-19 | 2007-02-13 | Sanofi-Aventis Deutschland Gmbh | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use |
ES2311806T3 (es) * | 2003-03-07 | 2009-02-16 | Schering Corporation | Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia. |
JP2005015434A (ja) * | 2003-06-27 | 2005-01-20 | Kotobuki Seiyaku Kk | 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤 |
WO2005062824A2 (fr) * | 2003-12-23 | 2005-07-14 | Merck & Co., Inc. | Composes anti-hypercholesterolemie |
EP1851197A2 (fr) * | 2005-02-09 | 2007-11-07 | Microbia, Inc. | Derives de phenylazetidinone |
JP2008543837A (ja) * | 2005-06-15 | 2008-12-04 | メルク エンド カムパニー インコーポレーテッド | 抗高コレステロール血症化合物 |
TW200806623A (en) * | 2005-10-05 | 2008-02-01 | Merck & Co Inc | Anti-hypercholesterolemic compounds |
DE102005055726A1 (de) * | 2005-11-23 | 2007-08-30 | Sanofi-Aventis Deutschland Gmbh | Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
CA2668094A1 (fr) * | 2006-11-02 | 2008-05-08 | Sanofi-Aventis Deutschland Gmbh | Nouvelle diphenylazetidinone substituee par l'acide piperazin-1-sulfonique presentant des proprietes pharmacologiques ameliorees |
-
2006
- 2006-09-26 TW TW095135631A patent/TW200806623A/zh unknown
- 2006-09-27 AR ARP060104231A patent/AR058068A1/es unknown
- 2006-09-29 CN CNA2006800369359A patent/CN101277930A/zh active Pending
- 2006-09-29 WO PCT/US2006/038551 patent/WO2007044318A2/fr active Application Filing
- 2006-09-29 DE DE602006018341T patent/DE602006018341D1/de active Active
- 2006-09-29 KR KR1020087008305A patent/KR20080050610A/ko not_active Application Discontinuation
- 2006-09-29 BR BRPI0616834A patent/BRPI0616834A2/pt not_active IP Right Cessation
- 2006-09-29 EP EP06816084A patent/EP1934175B1/fr active Active
- 2006-09-29 AT AT06816084T patent/ATE488495T1/de not_active IP Right Cessation
- 2006-09-29 ES ES06816084T patent/ES2354460T3/es active Active
- 2006-09-29 CA CA2624481A patent/CA2624481C/fr not_active Expired - Fee Related
- 2006-09-29 AU AU2006302584A patent/AU2006302584B2/en not_active Ceased
- 2006-09-29 JP JP2008534613A patent/JP4879991B2/ja not_active Expired - Fee Related
- 2006-09-29 EA EA200801008A patent/EA200801008A1/ru unknown
- 2006-09-29 US US11/992,990 patent/US20090137546A1/en not_active Abandoned
- 2006-10-03 PE PE2006001201A patent/PE20070493A1/es not_active Application Discontinuation
- 2006-10-03 GT GT200600444A patent/GT200600444A/es unknown
- 2006-10-04 US US11/542,966 patent/US7704988B2/en not_active Expired - Fee Related
- 2006-10-05 DO DO2006000211A patent/DOP2006000211A/es unknown
-
2008
- 2008-03-20 ZA ZA200802587A patent/ZA200802587B/xx unknown
- 2008-03-25 IL IL190434A patent/IL190434A0/en unknown
- 2008-04-04 TN TNP2008000153A patent/TNSN08153A1/en unknown
- 2008-04-04 SV SV2008002863A patent/SV2009002863A/es not_active Application Discontinuation
- 2008-04-18 CR CR9903A patent/CR9903A/es not_active Application Discontinuation
- 2008-05-02 MA MA30894A patent/MA30006B1/fr unknown
- 2008-05-02 NO NO20082075A patent/NO20082075L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
GT200600444A (es) | 2007-05-04 |
TW200806623A (en) | 2008-02-01 |
WO2007044318A3 (fr) | 2007-07-12 |
CR9903A (es) | 2008-07-29 |
NO20082075L (no) | 2008-07-04 |
CA2624481C (fr) | 2012-04-03 |
AU2006302584B2 (en) | 2011-10-13 |
BRPI0616834A2 (pt) | 2016-08-23 |
SV2009002863A (es) | 2009-02-19 |
TNSN08153A1 (en) | 2009-10-30 |
US20070078098A1 (en) | 2007-04-05 |
US20090137546A1 (en) | 2009-05-28 |
WO2007044318A2 (fr) | 2007-04-19 |
KR20080050610A (ko) | 2008-06-09 |
JP2009511475A (ja) | 2009-03-19 |
DE602006018341D1 (de) | 2010-12-30 |
AR058068A1 (es) | 2008-01-23 |
ES2354460T3 (es) | 2011-03-15 |
IL190434A0 (en) | 2008-11-03 |
ZA200802587B (en) | 2009-06-24 |
AU2006302584A1 (en) | 2007-04-19 |
JP4879991B2 (ja) | 2012-02-22 |
ATE488495T1 (de) | 2010-12-15 |
DOP2006000211A (es) | 2007-05-31 |
PE20070493A1 (es) | 2007-06-13 |
EP1934175A2 (fr) | 2008-06-25 |
CN101277930A (zh) | 2008-10-01 |
US7704988B2 (en) | 2010-04-27 |
EA200801008A1 (ru) | 2009-02-27 |
EP1934175B1 (fr) | 2010-11-17 |
CA2624481A1 (fr) | 2007-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30006B1 (fr) | Composes anti-hypercholesterolemiques | |
MA29647B1 (fr) | Agonistes du recepteur de la niacine, compositions contenant de tels composes et procedes de traitement | |
MA30412B1 (fr) | Composés Pharmaceutiques | |
MA35285B1 (fr) | Indazoles | |
MA30781B1 (fr) | Inhibiteur de kinase | |
NO20090025L (no) | Pyrrolotriazinkinaseinhibitorer | |
PT1940839E (pt) | Inibidores de piridopirimidinona pi3k alfa | |
MA27781A1 (fr) | 3-fluoro-piperidines comme antagonistes de nmda/nr2b. | |
MA35643B1 (fr) | Inhibiteur de cetp d'oxazolidinone bicyclique condensée | |
WO2006138163A3 (fr) | Composes anti-hypercholesterolemiques | |
WO2007120647A3 (fr) | Compositions utiles en tant qu'inhibiteurs de canaux sodiques sensibles a la tension | |
MA31373B1 (fr) | Composes amino-heterocycliques | |
HK1085728A1 (en) | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia | |
HK1119699A1 (en) | Pyridopyrimidinone inhibitors of pi3kalpha | |
HK1085727A1 (en) | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia | |
MA32135B1 (fr) | Inhibiteurs de pim kinase et leurs procedes d'utilisation | |
WO2005062824A3 (fr) | Composes anti-hypercholesterolemie | |
MA25809A1 (fr) | Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase | |
YU84603A (sh) | Novi inhibitori tirozin kinaze | |
MXPA04002167A (es) | Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes. | |
NO20056192L (no) | Kapaseinhibitorer og anvendelse derav | |
MA30420B1 (fr) | Derives de terphenyle pour le traitment de la maladie d'alzheimer | |
TW200733976A (en) | Method for the treatment of cognitive dysfunction | |
MA30821B1 (fr) | Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes | |
NO20092035L (no) | Tiazolylforbindelser anvendbare som kinaseinhibitorer |